Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Pharm |
RCV001787329 | SCV000494720 | drug response | peginterferon alfa-2b and ribavirin response - Toxicity | 2021-03-24 | reviewed by expert panel | curation | PharmGKB Level of Evidence 2B: Variants in Level 2B clinical annotations are not in PharmGKB’s Tier 1 VIPs. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2B clinical annotations must be supported by at least two independent publications. |
Labcorp Genetics |
RCV000015868 | SCV001726919 | benign | Inosine triphosphatase deficiency | 2025-01-22 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001675581 | SCV001893443 | benign | not provided | 2021-05-12 | criteria provided, single submitter | clinical testing | This variant is associated with the following publications: (PMID: 19579612, 12384777, 20547162, 22613675, 17113761, 20173735, 22939045) |
Genome- |
RCV001730474 | SCV001980785 | benign | Developmental and epileptic encephalopathy, 35 | 2021-08-19 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000015868 | SCV000036135 | affects | Inosine triphosphatase deficiency | 2002-10-01 | no assertion criteria provided | literature only |